Page last updated: 2024-11-08

tamitinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID3085156
CHEMBL ID307214
SCHEMBL ID1816376
MeSH IDM0067300

Synonyms (17)

Synonym
emd-21657
tamitinol [inn:ban]
tamitinol
CHEMBL307214
4-(ethylaminomethyl)-2-methyl-5-(methylsulfanylmethyl)pyridin-3-ol
3-pyridinol, 4-((ethylamino)methyl)-2-methyl-5-((methylthio)methyl)-
4-((ethylamino)methyl)-2-methyl-5-((methylthio)methyl)-3-pyridinol
9h440nf95e ,
59429-50-4
unii-9h440nf95e
tamitinol [inn]
SCHEMBL1816376
DTXSID30208153
4-ethylaminomethyl-2-methyl-5-methylthiomethyl-3-pyridinol
Q27272554
EN300-255024
4-[(ethylamino)methyl]-2-methyl-5-[(methylsulfanyl)methyl]pyridin-3-ol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 20 patients of the control group were treated during this period with maprotiline of the same dosage but did not received EMD 21 657 as co-medication."( Neurotropic drugs as co-medication to psychotropics. Combined administration of a neurotropic drug and a tetracyclic antidepressant.
Pöldinger, W; Reinhardt, B, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (66.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]